Jeremy D. Rubinstein

发表

Cyclic AMP Signaling Inhibits Megakaryocytic Differentiation by Targeting Transcription Factor 3 (E2A) Cyclin-dependent Kinase Inhibitor 1A (CDKN1A) Transcriptional Axis*

K. E. Elagib, A. Goldfarb, Jeremy D. Rubinstein, 2012, The Journal of Biological Chemistry.

Off the Shelf Third Party Virus Specific T-Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplant Recipients

P. Hanley, C. Bollard, J. Cancelas, 2021, Transplantation and Cellular Therapy.

Calpain 2 activation of P-TEFb drives megakaryocyte morphogenesis and is disrupted by leukemogenic GATA1 mutation.

S. Orkin, Zhe Li, P. Greer, 2013, Developmental cell.

Chimeric antigen receptor T‐cell therapy in patients with neurologic comorbidities

Thomas C. Badgett, S. Davies, Jeremy D. Rubinstein, 2020, Pediatric blood & cancer.

Chimeric antigen receptor T-cell therapy in patients with multiply relapsed or refractory extramedullary leukemia.

S. Davies, M. O'Brien, Jeremy D. Rubinstein, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis

C. Dandoy, B. Weiss, Jennifer Young, 2020, Pediatric blood & cancer.

Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy.

P. Hanley, C. Bollard, J. Cancelas, 2020, Blood advances.

Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.

P. Hanley, C. Bollard, J. Cancelas, 2020, Blood advances.

Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short‐course EPOCH regimens are safe and effective

R. Norris, M. Absalon, J. Perentesis, 2021, Pediatric blood & cancer.

Cyclic AMP signaling inhibits megakaryocytic differentiation by targeting a transcription factor 3 (E2A) cyclic dependent kinase inhibitor 1A (CDKN1A) transcriptional axis*

A. Goldfarb, Jeremy D. Rubinstein, K. Elagib, 2012 .

Endothelial injury, F-actin and vitamin D binding protein after hematopoietic stem cell transplant and association with clinical outcomes

S. Davies, S. Jodele, Nathan Luebbering, 2020, Haematologica.

Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.

A. Sette, P. Hanley, C. Bollard, 2021, Blood advances.

Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders

Karen M. Chisholm, C. Mason, Tamara P. Miller, 2022, Cancer.

EBV‐directed viral‐specific T‐lymphocyte therapy for the treatment of EBV‐driven lymphoma in two patients with primary immunodeficiency and DNA repair defects

P. Hanley, M. Absalon, C. Lutzko, 2019, Pediatric blood & cancer.

Acute myeloid leukemia in SRP54‐mutated congenital neutropenia

K. Myers, S. Davies, Anthony Sabulski, 2022, EJHaem.

Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults.

Jeremy D. Rubinstein, K. Toner, B. Wistinghausen, 2023, Best practice & research. Clinical haematology.

Third party and patient-specific donor-derived virus-specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplant in children and young adults.

P. Hanley, C. Bollard, J. Cancelas, 2023, Transplantation and cellular therapy.

Burkitt lymphoma after solid‐organ transplant: Treatment and outcomes in the paediatric PTLD collaborative

Karen M. Chisholm, C. Mason, Tamara P. Miller, 2022, British journal of haematology.

Surgical and anesthetic management for hepatectomy in two pediatric patients with trisomy 18, pulmonary hypertension, and hepatoblastoma

J. Pratap, G. Tiao, J. Geller, 2019, Pediatric blood & cancer.

Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia

C. Zwaan, H. van Tinteren, P. Bader, 2022, Leukemia.

Durable remissions achieved with reinfusion of CD19‐directed CAR‐T despite failure to induce or maintain B‐cell aplasia and single‐center experience with reinfusion of tisagenlecleucel

S. Davies, C. Dandoy, Jeremy D. Rubinstein, 2023, Pediatric blood & cancer.

Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant

P. Hanley, C. Bollard, J. Cancelas, 2022, Blood advances.

The choice of either conventional chemotherapy or inotuzumab ozogamicin as bridging regimen does not appear to impact clinical response to CD19-directed CAR-T therapy in pediatric B-ALL.

R. Norris, C. Dandoy, Erin H. Breese, 2023, Transplantation and cellular therapy.

Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells

J. Bennett, P. Keeney, Jeremy D. Rubinstein, 2008, Molecular Neurodegeneration.

Use of gemcitabine, oxaliplatin, and anti‐CD20 therapy in children and adolescents with non‐Hodgkin lymphoma unfit for intensive therapy

J. Perentesis, B. Mizukawa, Jeremy D. Rubinstein, 2023, Pediatric blood & cancer.

Expanding the pediatric oncology medical home: Successful utilization of a medical‐legal partnership at a pediatric oncology referral center

Melissa D. Klein, J. Pressey, Jeremy D. Rubinstein, 2019, Pediatric Blood & Cancer.

Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience

S. Davies, C. Dandoy, Jeremy D. Rubinstein, 2023, Frontiers in Hematology.

Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues.

J. Bennett, R. Capaldi, P. Keeney, 2009, Biochimica et biophysica acta.

Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

C. Zwaan, F. Locatelli, P. Bader, 2021, Blood.

Post‐transplant lymphoproliferative disease in children, adolescents, and young adults

T. Gross, Jeremy D. Rubinstein, 2023, Hematological oncology.

Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis

Vanessa L. Horner, R. Kanagal-Shamanna, J. Churpek, 2023, Leukemia.

Pediatric and Young Adult Vulvovaginal Graft-versus-Host Disease.

K. Myers, C. Dandoy, Jeremy D. Rubinstein, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations

Jeremy D. Rubinstein, M. O’Brien, 2023, Frontiers in immunology.

An exceptional case of durable remission achieved with reinfusion of CD19-directed CAR-T despite failure to induce B-cell aplasia and review of institutional experience with reinfusion of tisagenlecleucel

S. Davies, C. Dandoy, Jeremy D. Rubinstein, 2022 .

Virus-Specific T Cells for the Treatment of Systemic Infections Following Allogeneic Hematopoietic Cell and Solid Organ Transplantation.

Jeremy D. Rubinstein, M. Grimley, Thomas Pfeiffer, 2024, Journal of the Pediatric Infectious Diseases Society.